EXHIBIT 99.1

Appendix 4C

Quarter Ended 31 March 2016

San Diego, California and Sydney, Australia (Friday, 29 April 2016, AEST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) is pleased to provide the attached Appendix 4C Quarterly Report for the quarter ended 31 March 2016. The Appendix 4C is unaudited.

First Quarter Highlights

During the first quarter of 2016, the Company’s operating activities continued to focus on the clinical study of its Fantom scaffold. In February 2016, the Company announced it had reached targeted enrollment of 110 patients in Cohort B of the FANTOM II clinical trial. Combined with the patients enrolled in Cohort A, which completed enrollment in October 2015 with 117 patients, a total of 240 patients are enrolled in the trial. Fantom is a bioresorbable drug-eluting scaffold that utilizes REVA’s advanced proprietary polymer to allow thinner strut thickness and enhanced deliverability, while offering its unique property of being visible under x-ray.

Patients in Cohort A are undergoing imaging assessments at six months with all patients anticipated to be assessed by early May. Data from the Cohort A patients are planned to be used in a CE Mark application during the third quarter of this year. If approved, the CE Mark would allow REVA to sell in Europe and other countries that recognize the CE Mark. Patients in Cohort B are undergoing imaging assessments at nine months and data from this second set of patients will be used for market support and other commercial purposes.

The Company is preparing to release the six-month imaging results on a majority of the patients in Cohort A at the Paris Course on Revascularization (“EuroPCR”), which is being held May 16^th through May 20^th in Paris, France. This will be the first public release of the six-month data; previous early data presented on the FANTOM II patients showed very good procedural success and low MACE rates through three months and those interim results confirmed sustained restoration of blood flow.

In addition to the clinical progress during the first quarter, the Company continued its technical progress related to processes and refinement of Fantom to support the scale-up of manufacturing and, in support of preparing for commercialization, announced the hiring of Mr. Richard Kimes as Sr. Vice President of Operations in January 2016. Also, in March 2016, the Board appointed long-term director Brian Dovey to be Chairman, replacing Robert B. Stockman, who remains on the Board.

On 12 February 2016, the Company announced receipt of US$11,407,000 cash proceeds from the issuance of 4,375,000 shares of common stock upon the exercise of warrants. The warrants had been issued under the convertible note financing on 14 November 2014 and, following this exercise, no other warrants remain outstanding. In connection with the exercise, the Company entered into an amendment of the Note Deed governing the convertible notes. The amendment, which was approved by stockholders at a Special Meeting on March 22, 2016, provided two modifications. The first modification extended the date of an optional redemption right of the noteholders to 30 June 2017; the prior optional redemption date had been 14 January 2017. The second modification added a third

__________________________________________________________________________________________

HEAD OFFICE:  5751 Copley Drive, San Diego, CA 92111   •   +1 (858) 966-3000   •   +1 (858) 966-3099 (FAX)   •   www.revamedical.com

AUSTRALIAN OFFICE: Suite 4, Level 14, 6 O’Connell Street, Sydney NSW 2000   •   +61 2 9237 2800

ARBN 146 505 777   •   REVA Medical, Inc., is a foreign company incorporated in Delaware, USA, whose stockholders have limited liability

REVA Medical, Inc. – ASX AnnouncementPage 2

condition, being that the Company list its common stock on the NASDAQ stock exchange (or another exchange approved by the noteholders), before the Notes will automatically convert into common stock. The prior conditions to an automatic conversion of the Notes were the receipt of a CE Mark on Fantom combined with a market trading price of the Company’s securities of at least A$0.60 per CDI for 20 or more consecutive trading days.

Appendix 4C

As of 31 March 2016, the Company’s cash balance was US$22,073,000. The current quarter end cash balance reflects an increase of US$5,178,000 from the 31 December 2015 balance of US$16,895,000. This increase reflects the receipt of the US$11,407,000 warrant exercise proceeds and US$8,000 in employee plan option exercise proceeds. These receipts were offset by US$6,038,000 in disbursements related to normal operating activities and capital equipment purchases of US$199,000.

The Company currently plans to file its Form 10-Q Quarterly Report with the U.S. Securities and Exchange Commission and with the Australian Securities Exchange on or before the due date of 10 May 2016. The Quarterly Report provides financial statements, along with Management’s Discussion and Analysis of Financial Condition and Results of Operations for the quarter ended 31 March 2016.

About REVA

REVA is a clinical stage medical device company located in San Diego, California, USA, that is working to commercialize its proprietary bioresorbable stents, which are called “scaffolds”. The Company’s scaffolds have been developed as an alternative to metal stents, which are small tube-like devices permanently implanted into an artery to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s initial product, the Fantom^® scaffold, has been designed to offer an ideal balance of thinness and strength and distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require successful clinical trial results and regulatory approval before it can commercialize Fantom or any other product.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding our ability to obtain regulatory approvals, timely and successfully complete our clinical trials, protect our intellectual property position, commercialize our products if and when approved, develop and commercialize new products, recruit and retain our key personnel, and estimates regarding our capital requirements and financial performance. You should not place undue reliance on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the “SEC”) on March 10, 2016, and as may be updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

__________________________________________________________________________________________

HEAD OFFICE:  5751 Copley Drive, San Diego, CA 92111   •   +1 (858) 966-3000   •   +1 (858) 966-3099 (FAX)   •   www.revamedical.com

AUSTRALIAN OFFICE: Suite 4, Level 14, 6 O’Connell Street, Sydney NSW 2000   •   +61 2 9237 2800

ARBN 146 505 777   •   REVA Medical, Inc., is a foreign company incorporated in Delaware, USA, whose stockholders have limited liability

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Rule 4.7B

Appendix 4C

Quarterly report

for entities admitted

on the basis of commitments

Introduced 31/03/00  Amended 30/09/01, 24/10/05, 17/12/10

Consolidated statement of cash flows

+ See chapter 19 for defined terms.

17/12/2010Appendix 4C Page 1

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

+ See chapter 19 for defined terms.

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

Non-cash financing and investing activities

Financing facilities available

Add notes as necessary for an understanding of the position.

+ See chapter 19 for defined terms.

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Reconciliation of cash

Acquisitions and disposals of business entities

Compliance statement

(Chief Financial Officer/Company Secretary)

Print name:  Katrina L. Thompson

+ See chapter 19 for defined terms.

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Notes

+ See chapter 19 for defined terms.